Pirfenidone Solution for Inhalation

DRUG3 trials

Sponsors

Avalyn Pharma Inc.

Conditions

Interstitial Lung Diseases (ILD)Progressive Pulmonary FibrosisProgressive pulmonary fibrosis [PPF] Idiopathic pulmonary fibrosis [IPF]including but not limited to idiopathic pulmonary fibrosis (IPF)

Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)

RecruitingCTIS2023-508429-29-00

Avalyn Pharma Inc.Progressive Pulmonary Fibrosis

Start: 2024-09-26Target: 182Updated: 2026-01-22

Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis

CompletedCTIS2024-515964-30-00

Avalyn Pharma Inc.including but not limited to idiopathic pulmonary fibrosis (IPF), Interstitial Lung Diseases (ILD)

Start: 2021-07-14End: 2025-08-18Target: 33Updated: 2025-06-18

A Multinational, Long-Term, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [Sail])

RecruitingCTIS2024-518289-28-00

Avalyn Pharma Inc.Progressive pulmonary fibrosis [PPF] Idiopathic pulmonary fibrosis [IPF]

Start: 2025-07-04Target: 121Updated: 2026-01-26